Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma

doi:10.1002/cld.810

Review

. 2019 Sep 2;14(2):62-65.

doi: 10.1002/cld.810. eCollection 2019 Aug.

Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma

Samantha Sarcognato^{1

2}, Teresa García-Lezana¹, Augusto Villanueva^{1

3}

Affiliations

¹ Liver Cancer Program, Division of Liver Diseases, Department of Medicine Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York NY.
² Surgical Pathology & Cytopathology Unit, Department of Medicine-DIMED University of Padova Padova Italy.
³ Division of Hematology and Medical Oncology, Department of Medicine Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York NY.

PMID: 31508222
PMCID: PMC6726381
DOI: 10.1002/cld.810

Review

Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma

Samantha Sarcognato et al. Clin Liver Dis (Hoboken). 2019.

. 2019 Sep 2;14(2):62-65.

doi: 10.1002/cld.810. eCollection 2019 Aug.

Authors

Samantha Sarcognato^{1

2}, Teresa García-Lezana¹, Augusto Villanueva^{1

3}

Affiliations

¹ Liver Cancer Program, Division of Liver Diseases, Department of Medicine Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York NY.
² Surgical Pathology & Cytopathology Unit, Department of Medicine-DIMED University of Padova Padova Italy.
³ Division of Hematology and Medical Oncology, Department of Medicine Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York NY.

PMID: 31508222
PMCID: PMC6726381
DOI: 10.1002/cld.810

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Depiction of the targets and pathways inhibited by the drugs effective in patients with HCC. At the top of the figure, rectangles represent the specificity, and their size correlates with the affinity of each drug to the target: big rectangles, IC₅₀ ≤10 nM; medium rectangles, IC₅₀ 10 to 50 nM; small rectangles, IC₅₀ ≥50 nM.

See this image and copyright information in PMC

Cited by

Astragaloside IV Induces Apoptosis, G₁-Phase Arrest and Inhibits Anti-apoptotic Signaling in Hepatocellular Carcinoma.
Su CM, Wang HC, Hsu FT, Lu CH, Lai CK, Chung JG, Kuo YC. Su CM, et al. In Vivo. 2020 Mar-Apr;34(2):631-638. doi: 10.21873/invivo.11817. In Vivo. 2020. PMID: 32111763 Free PMC article.
TUG1 long non-coding RNA enlists the USF1 transcription factor to overexpress ROMO1 leading to hepatocellular carcinoma growth and metastasis.
Liu S, Qiu J, He W, Geng C, He G, Liu C, Cai D, Liu X, Tian B, Pan H. Liu S, et al. MedComm (2020). 2020 Nov 26;1(3):386-399. doi: 10.1002/mco2.38. eCollection 2020 Dec. MedComm (2020). 2020. PMID: 34766130 Free PMC article.
Induction of Apoptosis by Isoalantolactone in Human Hepatocellular Carcinoma Hep3B Cells through Activation of the ROS-Dependent JNK Signaling Pathway.
Kim MY, Lee H, Ji SY, Kim SY, Hwangbo H, Park SH, Kim GY, Park C, Leem SH, Hong SH, Choi YH. Kim MY, et al. Pharmaceutics. 2021 Oct 6;13(10):1627. doi: 10.3390/pharmaceutics13101627. Pharmaceutics. 2021. PMID: 34683920 Free PMC article.
Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma.
Okubo H, Ando H, Takasaki Y, Nakadera E, Fukuo Y, Shiina S, Ikejima K. Okubo H, et al. Pharmaceuticals (Basel). 2022 Nov 25;15(12):1460. doi: 10.3390/ph15121460. Pharmaceuticals (Basel). 2022. PMID: 36558911 Free PMC article.
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease.
He Q, He W, Dong H, Guo Y, Yuan G, Shi X, Wang D, Lu F. He Q, et al. Cell Commun Signal. 2024 Jun 28;22(1):346. doi: 10.1186/s12964-024-01720-9. Cell Commun Signal. 2024. PMID: 38943171 Free PMC article. Review.

See all "Cited by" articles

References

1. Zucman‐Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149:1226‐1239. - PubMed
1. Llovet JM, Zucman‐Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018‐16023. - PubMed
1. Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599‐616. - PubMed
1. European Association for the Study of the Liver . EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182‐236. - PubMed
1. Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408‐424. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Zucman‐Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149:1226‐1239. - PubMed

[2] Zucman‐Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149:1226‐1239. - PubMed

[3] Llovet JM, Zucman‐Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018‐16023. - PubMed

[4] Llovet JM, Zucman‐Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018‐16023. - PubMed

[5] Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599‐616. - PubMed

[6] Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599‐616. - PubMed

[7] European Association for the Study of the Liver . EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182‐236. - PubMed

[8] European Association for the Study of the Liver . EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182‐236. - PubMed

[9] Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408‐424. - PubMed

[10] Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408‐424. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma

Affiliations

Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources